Press Releases
Samsung Biologics Presents at BIO2020 Encore
Samsung Biologic Presents Speaker Sessions at BPI Theater 2020
-
- Kevin Sharp
- Senior Director, Business Development
- Richard Lee
- Head of Drug Product Business Unit
- Dan Slone
- Vp & Head of Downstream Manufacturing
- John Gill
- Director, Cell Line Development
- Justin Carbungco
- Associate Director, sCMO Operations
BIO 2020 Encore brings back our speaker series at BioProcess International Theatre, which will be held from 8th~9th of July. The conference will hold discussions on two main topics: Emerging Therapies and Emerging Techniques, Technologies, and Strategies. There are 5 speakers from Samsung Biologics participating this year at five different sessions. Justin Carbungco, Associate Director of Small Scale Manufacturing will discuss studies on "Economics of Stainless Steel and Single-Use Systems" on July 8th at 3:15pm. At 4:15pm, John Gill, Director of Cell Line Development will talk about "Accelerated & High Performance Cell Line Development". On July 9th at 2:30pm, Richard Lee, Head of Drug Product Business Unit will share studies on "Securing Your Manufacturing Capacity During the Pandemic". For the on-demand sessions, Daniel Slone, VP & Head of Downstream Manufacturing joins in as the panel to discuss on "The Evolving Role of the Outsourcing Manufacturer: Why CDMO Is the New Normal". Also Kevin Sharp, Director Business Development sits down with Bioprocess Insider editor to discuss Samsung Biologics' response to the COVID-19 pandemic. To learn more about our sessions, visit here.
Samsung Biologic Presents Speaker Sessions at BPI Theater 2020
-
- Kevin Sharp
- Senior Director, Business Development
- Richard Lee
- Head of Drug Product Business Unit
- Dan Slone
- Vp & Head of Downstream Manufacturing
- John Gill
- Director, Cell Line Development
- Justin Carbungco
- Associate Director, sCMO Operations
BIO 2020 Encore brings back our speaker series at BioProcess International Theatre, which will be held from 8th~9th of July. The conference will hold discussions on two main topics: Emerging Therapies and Emerging Techniques, Technologies, and Strategies.
There are 5 speakers from Samsung Biologics participating this year at five different sessions.
Justin Carbungco, Associate Director of Small Scale Manufacturing will discuss studies on "Economics of Stainless Steel and Single-Use Systems" on July 8th at 3:15pm. At 4:15pm, John Gill, Director of Cell Line Development will talk about "Accelerated & High Performance Cell Line Development". On July 9th at 2:30pm, Richard Lee, Head of Drug Product Business Unit will share studies on "Securing Your Manufacturing Capacity During the Pandemic".
For the on-demand sessions, Daniel Slone, VP & Head of Downstream Manufacturing joins in as the panel to discuss on "The Evolving Role of the Outsourcing Manufacturer: Why CDMO Is the New Normal". Also Kevin Sharp, Director Business Development sits down with Bioprocess Insider editor to discuss Samsung Biologics' response to the COVID-19 pandemic.
To learn more about our sessions, visit here.